1. Academic Validation
  2. PLEKHG5 deficiency leads to an intermediate form of autosomal-recessive Charcot-Marie-Tooth disease

PLEKHG5 deficiency leads to an intermediate form of autosomal-recessive Charcot-Marie-Tooth disease

  • Hum Mol Genet. 2013 Oct 15;22(20):4224-32. doi: 10.1093/hmg/ddt274.
Hamid Azzedine 1 Petra Zavadakova Violaine Planté-Bordeneuve Maria Vaz Pato Nuno Pinto Luca Bartesaghi Jennifer Zenker Olivier Poirot Nathalie Bernard-Marissal Estelle Arnaud Gouttenoire Romain Cartoni Alexandra Title Giulia Venturini Jean-Jacques Médard Edward Makowski Ludger Schöls Kristl G Claeys Claudia Stendel Andreas Roos Joachim Weis Odile Dubourg José Leal Loureiro Giovanni Stevanin Gérard Said Anthony Amato Jay Baraban Eric LeGuern Jan Senderek Carlo Rivolta Roman Chrast
Affiliations

Affiliation

  • 1 These authors contributed equally to this work.
Abstract

Charcot-Marie-Tooth disease (CMT) comprises a clinically and genetically heterogeneous group of peripheral neuropathies characterized by progressive distal muscle weakness and atrophy, foot deformities and distal sensory loss. Following the analysis of two consanguineous families affected by a medium to late-onset recessive form of intermediate CMT, we identified overlapping regions of homozygosity on chromosome 1p36 with a combined maximum LOD score of 5.4. Molecular investigation of the genes from this region allowed identification of two homozygous mutations in PLEKHG5 that produce premature stop codons and are predicted to result in functional null alleles. Analysis of Plekhg5 in the mouse revealed that this gene is expressed in neurons and glial cells of the peripheral nervous system, and that knockout mice display reduced nerve conduction velocities that are comparable with those of affected individuals from both families. Interestingly, a homozygous PLEKHG5 missense mutation was previously reported in a recessive form of severe childhood onset lower motor neuron disease (LMND) leading to loss of the ability to walk and need for respiratory assistance. Together, these observations indicate that different mutations in PLEKHG5 lead to clinically diverse outcomes (intermediate CMT or LMND) affecting the function of neurons and glial cells.

Figures